SCPH Insider Trading
Insider Ownership Percentage: 5.52%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
scPharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at scPharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
scPharmaceuticals Share Price & Price History
Current Price: $2.32
Price Change: ▲ Price Increase of +0.02 (0.87%)
As of 04/4/2025 05:00 PM ET
scPharmaceuticals Insider Trading History
scPharmaceuticals Institutional Trading History
Data available starting January 2016
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Read More on scPharmaceuticals
Volume
570,812 shs
Average Volume
342,515 shs
Market Capitalization
$116.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.38